FDA Issues Complete Response Letter to Alimera Sciences Regarding New Drug Application for ILUVIEN(R)

ATLANTA, Dec. 23, 2010 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq:ALIM) (“Alimera”), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for the investigational drug [...] http://bit.ly/ez4SgL